Peter Eickelmann
-
- Diabetes Treatment and Management 3
- Toxicology top 5%
-
- Genomics, phytochemicals, and oxidative stress 6
- Glutathione Transferases and Polymorphisms 4
- Chemical Synthesis and Analysis 3
- Receptor Mechanisms and Signaling 3
- Coenzyme Q10 studies and effects 2
- Surgery top 10%
- Pancreatic function and diabetes 6
- Nephrology top 10%
-
- Neuropeptides and Animal Physiology 3
Peter Eickelmann
19 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Endocrinology, Diabetes and Metabolism 534
- Toxicology 54
- Molecular Biology 662
- Surgery 408
- Nephrology 41
Countries citing papers authored by Peter Eickelmann
This map shows the geographic impact of Peter Eickelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Eickelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Eickelmann more than expected).
Fields of papers citing papers by Peter Eickelmann
This network shows the impact of papers produced by Peter Eickelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Eickelmann. The network helps show where Peter Eickelmann may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Eickelmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 24 | |
| 2 | 2012 | 30 | |
| 3 | 2011 | 42 | |
| 4 | Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsbreakdown → | 2011 | 494 |
| 5 | 2011 | 60 | |
| 6 | 2007 | 12 | |
| 7 | 2003 | 31 | |
| 8 | 2003 | 37 | |
| 9 | 2002 | 20 | |
| 10 | 1997 | 135 | |
| 11 | 1996 | 8 | |
| 12 | 1996 | 12 | |
| 13 | 1995 | 8 | |
| 14 | 1995 | 2 | |
| 15 | 1995 | 1 | |
| 16 | 1994 | 46 | |
| 17 | 1994 | 28 | |
| 18 | Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase alpha messenger RNA in human renal cell carcinoma. | 1994 | 30 |
| 19 | 1991 | 29 |
About Peter Eickelmann
Peter Eickelmann is a scholar working on Physiology, Toxicology, Biochemistry, Cellular and Molecular Neuroscience and Molecular Biology, having authored 19 papers that have together received 1.0k indexed citations. Recurring topics across this work include Genomics, phytochemicals, and oxidative stress (6 papers), Pancreatic function and diabetes (6 papers), Glutathione Transferases and Polymorphisms (4 papers), Chemical Synthesis and Analysis (3 papers), Receptor Mechanisms and Signaling (3 papers), Diabetes Treatment and Management (3 papers), Neuropeptides and Animal Physiology (3 papers) and Coenzyme Q10 studies and effects (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (534 citations), Toxicology (54 citations), Molecular Biology (662 citations), Surgery (408 citations) and Nephrology (41 citations). Peter Eickelmann has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Michael Mark, Rolf Grempler, Thomas Klein, Frank Himmelsbach, Achim Sauer, Leo Thomas, Matthias Eckhardt, Remko A. Bakker, Dale E. Sharp and Helmut Sies. Their work appears in journals such as FEBS Letters, European Journal of Biochemistry, Diabetes Obesity and Metabolism, Carcinogenesis and Journal of Peptide Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.